Form 4: IRADIMED CEO Sells Shares Under 10b5-1 Plan

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold a total of 5,000 shares of common stock on December 29, 2025, through a pre-arranged 10b5-1 trading plan.

Summary

• Roger E. Susi, the CEO, President, Chairman, Director, and 10% Owner of IRADIMED CORP (IRMD), reported sales of common stock.
• On December 29, 2025, Susi sold 4,899 shares of common stock at a weighted average price of $97.65 per share.
• On the same date, an additional 101 shares of common stock were sold at a weighted average price of $98.31 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Roger E. Susi on June 16, 2025.
• Following these transactions, beneficial ownership includes 2,282,601 shares and 2,282,500 shares held indirectly by the Phillip Susi 2008 Dynasty Trust, 162,950 shares held indirectly by the Roger E. Susi Revocable Trust, and 2,062,500 shares held indirectly by the Matthew Susi 2008 Dynasty Trust.
• Roger E. Susi disclaims beneficial ownership of the securities held by the trusts except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The filing reports pre-planned insider sales under a Rule 10b5-1 plan, which are routine and do not inherently indicate a positive or negative outlook on the company's future performance.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and transparent approach to insider transactions rather than an immediate reaction to new information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, potentially leading to short-term downward pressure on the stock price.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Roger E. Susi undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Industry Context

This insider transaction report is specific to IRADIMED Corp and its CEO, Roger E. Susi, and does not provide broader industry context or trends.

Corporate Governance

Related Party Transactions

• Roger E. Susi's indirect beneficial ownership includes shares held by the Phillip Susi 2008 Dynasty Trust, Roger E. Susi Revocable Trust, and Matthew Susi 2008 Dynasty Trust, which are related entities.

Stakeholder Impact

• Shareholders may interpret insider selling, even if pre-planned, as a signal, potentially influencing short-term trading decisions.

Next Steps

• Roger E. Susi has undertaken to provide full information regarding the number of shares and prices of the transactions upon request.

Key Dates

Recommendation

The reported sales by the CEO were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new material information. While insider selling can sometimes be viewed negatively, the pre-planned nature mitigates immediate concerns about the company's short-term prospects. Investors should monitor future filings and company performance for more substantive signals.

Keywords

IRADIMED, IRMD, Insider Trading, Form 4, Stock Sale, CEO, Roger E. Susi, 10b5-1 Plan, Beneficial Ownership